TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porterโs Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE
6.1. Overview
6.2. Manufacturing
6.3. Formulation and Fill-Finish
6.4. Packaging and Labeling
6.5. Other services
7. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE
7.1. Overview
7.2. Biologic Drug Substance Manufacturing
7.3. Biologic Drug Product Manufacturing
8. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION
8.1. Overview
8.2. Commercial Operations
8.3. Clinical Operations
9. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE
9.1. Overview
9.2. Mammalian Expression Systems
9.3. Non-Mammalian Expression Systems
10. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE
10.1. Overview
10.2. Monoclonal Antibodies
10.3. Cell Therapy & Gene Therapy
10.4. Antibody-Drug Conjugates (ADCs)
10.5. Vaccines
10.6. Therapeutic Peptides & Proteins
10.7. Other Molecule Types
11. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA
11.1. Overview
11.2. Oncology
11.3. Autoimmune Diseases
11.4. Cardiovascular Diseases
11.5. Metabolic Diseases
11.6. Infectious Diseases.
11.7. Neurology
11.8. Other Therapeutic Areas
12. GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY REGION
12.1. Overview
12.1. North America
12.1.1. US
12.1.2. Canada
12.2. Europe
12.2.1. Germany
12.2.2. France
12.2.3. UK
12.2.4. Italy
12.2.5. Spain
12.2.6. Rest of Europe
12.3. Asia-Pacific
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. South Korea
12.3.5. Australia
12.3.6. Rest of Asia-Pacific
12.4. Rest of the World
12.4.1. Middle East
12.4.2. Africa
12.4.3. Latin America
13. COMPETITIVE LANDSCAPE
13.1. Overview
13.2. Competitive Analysis
13.3. Market Share Analysis
13.4. Major Growth Strategy in the Global Biotechnology Contract Manufacturing,
13.5. Competitive Benchmarking
13.6. Leading Players in Terms of Number of Developments in the Global Biotechnology Contract Manufacturing,
13.7. Key developments and Growth Strategies
13.7.1. New Product Launch/Service Deployment
13.7.2. Merger & Acquisitions
13.7.3. Joint Ventures
13.8. Major Players Financial Matrix
13.8.1. Sales & Operating Income, 2023
13.8.2. Major Players R&D Expenditure. 2023
14. COMPANY PROFILES
14.1. Lonza (Switzerland)
14.1.1. Company Overview
14.1.2. Financial Overview
14.1.3. Products Offered
14.1.4. Key Developments
14.1.5. SWOT Analysis
14.1.6. Key Strategies
14.2. THERMO FISHER SCIENTIFIC, INC. (US)
14.2.1. Company Overview
14.2.2. Financial Overview
14.2.3. Products Offered
14.2.4. Key Developments
14.2.5. SWOT Analysis
14.2.6. Key Strategies
14.3. Catalent, Inc. (US)
14.3.1. Company Overview
14.3.2. Financial Overview
14.3.3. Products Offered
14.3.4. Key Developments
14.3.5. SWOT Analysis
14.3.6. Key Strategies
14.4. Samsung Biologics (South Korea)
14.4.1. Company Overview
14.4.2. Financial Overview
14.4.3. Products Offered
14.4.4. Key Developments
14.4.5. SWOT Analysis
14.4.6. Key Strategies
14.5. WuXi Bilogics (China)
14.5.1. Company Overview
14.5.2. Financial Overview
14.5.3. Products Offered
14.5.4. Key Developments
14.5.5. SWOT Analysis
14.5.6. Key Strategies
14.6. Boehringer Ingelheim International GmbH (Germany)
14.6.1. Company Overview
14.6.2. Financial Overview
14.6.3. Products Offered
14.6.4. Key Developments
14.6.5. SWOT Analysis
14.6.6. Key Strategies
14.7. FUJIFILM Holding Corporation (Japan)
14.7.1. Company Overview
14.7.2. Financial Overview
14.7.3. Products Offered
14.7.4. Key Developments
14.7.5. SWOT Analysis
14.7.6. Key Strategies
14.8. ABBVIE, INC. (US)
14.8.1. Company Overview
14.8.2. Financial Overview
14.8.3. Products Offered
14.8.4. Key Developments
14.8.5. SWOT Analysis
14.8.6. Key Strategies
14.9. Eurofins Scientific (Luxembourg)
14.9.1. Company Overview
14.9.2. Financial Overview
14.9.3. Products Offered
14.9.4. Key Developments
14.9.5. SWOT Analysis
14.9.6. Key Strategies
14.10. Merck KgaA (Germany) (US)
14.10.1. Company Overview
14.10.2. Financial Overview
14.10.3. Products Offered
14.10.4. Key Developments
14.10.5. SWOT Analysis
14.10.6. Key Strategies
14.11. AGC, Inc. (Japan)
14.11.1. Company Overview
14.11.2. Financial Overview
14.11.3. Products Offered
14.11.4. Key Developments
14.11.5. SWOT Analysis
14.11.6. Key Strategies
14.12. Merck KgaA (Germany)
14.12.1. Company Overview
14.12.2. Financial Overview
14.12.3. Products Offered
14.12.4. Key Developments
14.12.5. SWOT Analysis
14.12.6. Key Strategies
14.13. JSR Corporation (Japan)
14.13.1. Company Overview
14.13.2. Financial Overview
14.13.3. Products Offered
14.13.4. Key Developments
14.13.5. SWOT Analysis
14.13.6. Key Strategies
15. APPENDIX
15.1. References
15.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 7 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 8 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 11 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 12 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 13 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 14 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 15 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 16 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 17 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 18 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 19 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 20 US: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 21 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 22 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 23 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 24 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 25 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 26 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 4 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 5 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 6 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 7 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 8 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 9 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 10 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 11 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 12 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 13 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 14 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 15 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 16 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 17 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 18 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 19 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 20 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 21 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 22 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 23 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 24 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 25 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 26 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 27 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 28 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 29 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 30 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 31 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 32 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 33 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 34 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 35 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 36 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 37 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 38 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 39 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 40 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 41 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 42 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 43 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 44 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 45 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 46 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 47 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 48 ASIAPACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 49 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 50 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 51 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 52 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 53 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 54 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 55 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 56 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 57 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 58 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 59 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 60 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 61 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 62 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 63 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 64 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 65 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 66 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 67 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 68 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 69 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 70 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 71 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 72 AUSTRALIA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 73 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 74 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 75 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 76 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 77 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 78 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 79 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 80 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 81 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 82 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 83 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 84 REST OF ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 85 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 86 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 87 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 88 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 89 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 90 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 91 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 92 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 93 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 94 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 95 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 96 MIDDLE EAST: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 97 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 98 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 99 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 100 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 101 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 102 AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 103 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SERVICE, 2019-2032 (USD BILLION)
TABLE 104 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY TYPE, 2019-2032 (USD BILLION)
TABLE 105 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SCALE OF OPERATION, 2019-2032 (USD BILLION)
TABLE 106 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY SOURCE, 2019-2032 (USD BILLION)
TABLE 107 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY MOLECULE, 2019-2032 (USD BILLION)
TABLE 108 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING
FIGURE 4 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY SERVICE, 2023
FIGURE 5 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY TYPE, 2023
FIGURE 6 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY SCALE OF OPERATION, 2023
FIGURE 7 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY SOURCE, 2023
FIGURE 8 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY MOLECULE, 2023
FIGURE 9 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY THERAPEUTIC AREA, 2023
FIGURE 10 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 11 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 12 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 13 ASIA-PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 14 REST OF THE WORLD: BIOTECHNOLOGY CONTRACT MANUFACTURING, SHARE (%), BY REGION, 2023
FIGURE 15 GLOBAL BIOTECHNOLOGY CONTRACT MANUFACTURING: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 16 LONZA (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 LONZA (SWITZERLAND): SWOT ANALYSIS
FIGURE 18 THERMO FISHER SCIENTIFIC, INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 THERMO FISHER SCIENTIFIC, INC. (US): SWOT ANALYSIS
FIGURE 20 CATALENT, INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 CATALENT, INC. (US): SWOT ANALYSIS
FIGURE 22 SAMSUNG BIOLOGICS (SOUTH KOREA): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 SAMSUNG BIOLOGICS (SOUTH KOREA): SWOT ANALYSIS
FIGURE 24 WUXI BILOGICS (CHINA).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 WUXI BILOGICS (CHINA).: SWOT ANALYSIS
FIGURE 26 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): SWOT ANALYSIS
FIGURE 28 FUJIFILM HOLDING CORPORATION (JAPAN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 FUJIFILM HOLDING CORPORATION (JAPAN): SWOT ANALYSIS
FIGURE 30 ABBVIE, INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 ABBVIE, INC. (US): SWOT ANALYSIS
FIGURE 32 EUROFINS SCIENTIFIC (LUXEMBOURG): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 EUROFINS SCIENTIFIC (LUXEMBOURG): SWOT ANALYSIS
FIGURE 34 AGC, INC. (JAPAN): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 AGC, INC. (JAPAN): SWOT ANALYSIS
FIGURE 36 MERCK KGAA (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 MERCK KGAA (GERMANY): SWOT ANALYSIS